Kimmel Paul L, Fwu Chyng-Wen, Nolin Thomas D, Schulman Ivonne H, Givens Shannon S, Wilkins Kenneth J, Mendley Susan R, Gipson Debbie S, Greer Raquel C, Norton Jenna M, Chan Kevin E, Eggers Paul W
Division of Kidney Urologic and Hematologic Diseases, National Institute of Diabetes Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
DLH, LLC, Bethesda, Maryland.
J Am Soc Nephrol. 2025 Jan 1;36(1):108-121. doi: 10.1681/ASN.0000000000000478. Epub 2024 Sep 3.
The rate of prescription of opioid medication decreased between 2011 and 2020 for patients with ESRD. The risk of death for dialysis and kidney transplant patients increased as morphine milligram equivalents in prescriptions increased.
Pain is important for patients with kidney failure, but opioid medication prescriptions are associated with morbidity and mortality. The Centers for Disease Control and Prevention issued opioid prescription guidelines in 2016 and 2022, associated with dramatically decreased prescription rates in the United States. It is critical to know whether nationwide opioid prescription rates for patients with kidney failure have decreased.
We analyzed the United States Renal Data System database from 2011 to 2020 to describe trends in the proportion of patients with ESKD who received one or more, or long-term, opioid prescriptions, examined factors associated with long-term opioid prescriptions, and evaluated associations of all-cause death with short-term or long-term opioid prescriptions.
From 2011 to 2022, the percentage of patients with kidney failure (dialysis and kidney transplant) who received at least one or more, or who had received long-term, opioid medication prescriptions decreased steadily, from 60% to 42%, and from 23% to 13%, respectively (both for trend < 0.001). The largest reductions in prescription rates were for hydrocodone and oxycodone. Similar trends existed for dialysis and kidney transplant patients. Women, the poor, and those in rural settings were more likely to receive long-term opioid prescriptions. Prescription rates were highest in White patients and those aged 45–64 years. Short-term and long-term opioid medication prescriptions were associated with higher mortality in both dialysis and kidney transplant patients.
The opioid prescription rates of patients with ESKD decreased between 2011 and 2020. Higher mortality risk was associated with both short-term and long-term opioid prescriptions. Mortality risk was monotonically associated with morphine milligram equivalents in patients with kidney failure who received long-term opioid prescriptions.
2011年至2020年期间,终末期肾病(ESRD)患者的阿片类药物处方率下降。随着处方中吗啡毫克当量的增加,透析和肾移植患者的死亡风险上升。
疼痛对肾衰竭患者很重要,但阿片类药物处方与发病率和死亡率相关。疾病控制与预防中心在2016年和2022年发布了阿片类药物处方指南,这与美国处方率的大幅下降有关。了解肾衰竭患者的全国阿片类药物处方率是否下降至关重要。
我们分析了2011年至2020年的美国肾脏数据系统数据库,以描述接受一种或多种或长期阿片类药物处方的终末期肾病患者比例的趋势,研究与长期阿片类药物处方相关的因素,并评估全因死亡与短期或长期阿片类药物处方的关联。
从2011年到2022年,接受至少一种或多种或长期阿片类药物处方的肾衰竭(透析和肾移植)患者百分比稳步下降,分别从60%降至42%,从23%降至13%(两者趋势均<0.001)。处方率下降最大的是氢可酮和羟考酮。透析和肾移植患者也存在类似趋势。女性、贫困人口和农村地区的人更有可能接受长期阿片类药物处方。白人患者和45 - 64岁的患者处方率最高。短期和长期阿片类药物处方与透析和肾移植患者的较高死亡率相关。
2011年至2020年期间,ESKD患者的阿片类药物处方率下降。短期和长期阿片类药物处方均与较高的死亡风险相关。在接受长期阿片类药物处方的肾衰竭患者中,死亡风险与吗啡毫克当量呈单调相关。